Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PR-104||PR104|PR 104||PR-104 is a hypoxia-activated prodrug that causes DNA cross-linking within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 17606726, PMID: 26116659).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||PR-104||Preclinical||Actionable||In a preclinical study, PR-104 inhibited growth of triple-receptor negative breast cancer cell lines under hypoxic culture conditions, regardless of their BRCA1 status (PMID: 25193512).||25193512|
|PALB2 dec exp||triple-receptor negative breast cancer||sensitive||PR-104||Preclinical||Actionable||In a preclinical study, knockdown of PALB2 enhanced growth inhibition by PR-104 in triple-negative breast cancer cell lines in culture (PMID: 25193512).||25193512|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|